bluebird bio has entered into a new Master Services Agreement with Henogen SRL, a Thermo Fisher Scientific company, effective September 15, 2024, for the manufacturing of lentiviral vector (LVV) used in its gene therapy product LYFGENIA. The agreement replaces the previous manufacturing contract that expired on September 15, 2024.Under the agreement, Henogen will be responsible for manufacturing LVV, conducting quality control, validation activities, stability testing, packaging, and shipping services for both clinical and commercial use. The contract includes a 12-quarter rolling forecast system for commercial LVV orders, with specific binding and semi-binding forecast periods.The agreement will remain effective until September 15, 2029, with automatic two-year renewal options. Either party may terminate the agreement for material breach, bankruptcy, or force majeure events. The contract includes standard provisions for warranties, liability limitations, confidentiality, and indemnification obligations.

bluebird bio has entered into a new Master Services Agreement with Henogen SRL, a Thermo Fisher Scientific company, effective September 15, 2024, for the manufacturing of lentiviral vector (LVV) used in its gene therapy product LYFGENIA. The agreement replaces the previous manufacturing contract that expired on September 15, 2024.Under the agreement, Henogen will be responsible for manufacturing LVV, conducting quality control, validation activities, stability testing, packaging, and shipping services for both clinical and commercial use. The contract includes a 12-quarter rolling forecast system for commercial LVV orders, with specific binding and semi-binding forecast periods.The agreement will remain effective until September 15, 2029, with automatic two-year renewal options. Either party may terminate the agreement for material breach, bankruptcy, or force majeure events. The contract includes standard provisions for warranties, liability limitations, confidentiality, and indemnification obligations.